Press Release

MLLSEQ: New sequencing service of the MLL Munich Leukemia Laboratory

„MLLSEQ: We are the next generation – Sequencing Services“ – is the new brand of the MLL Munich Leukemia Laboratory. Under this label, MLL now offers its extensive Next-Generation-Sequencing (NGS) knowledge - from library preparation to "sequencing only" - as well as detailed bioinformatics processing and also visualization of the generated data. MLLSEQ is primarily aimed at international senders, researchers and pharmaceutical companies who are conducting clinical studies and are looking for a strong partner with comprehensive expert and sequencing knowledge as well as high quality standards.

In the last more than ten years, the MLL Munich Leukemia Laboratory has gained a lot of experience in sequencing of panels, exomes, genomes and transcriptomes with NGS technology and would like to share its expertise with immediate effect. MLLSEQ sees itself as a partner in science and research and therefore pursues the goal of providing maximum support to other institutions in the field of NGS. The workflows are quality controlled in all steps and at the same time designed for high throughput through automation. Thus, up to 250 human genomes (WGS) with 90x coverage per week can be sequenced and rapidly bioinformatically processed by parallelized processing in the private cloud. Thus, MLLSEQ manages to complete a whole-genome sequencing (WGS) and provide the results after only 10 days. The bioinformatics pipelines set up for this purpose are accredited and comply with all data protection requirements in accordance with the German Data Protection Regulation (DSGVO).

Besides the targeted NGS panels, which are also used in the daily MLL routine for the diagnosis of leukemias and lymphomas, MLLSEQ offers a CHIP (Clonal Hematopoiesis of indeterminate potential) panel, which is e.g. of interest for cardiological patients - as well as any other form of customized panel. In the latter case, MLLSEQ collaborates with IDT - Integrated DNA Technologies, whose panel design can be tested and optimized in silico and then also in the laboratory in 5-6 weeks at short notice.

MLL's sequencing service was founded a few years ago as MLL Dx GmbH, and now the Munich-based diagnostics laboratory headed by Dr. Manja Meggendorfer, Prof. Dr. Claudia Haferlach, Prof. Dr. Dr. Torsten Haferlach and Prof. Dr. Wolfgang Kern has created a new brand and corporate identity, including a new website (www.mllseq.com), in an exciting process together with the BLACKSPACE design studio. In the new MLLSEQ logo in deep purple the independence of the label appears with a clear association to the big sister company MLL. Maximum quality standards, flexibility and fast turnaround times are therefore also the credo at MLLSEQ. The Services of MLLSEQ are accredited according to ISO 15189 and 17025 and Illumina Propel certified. CAP accreditation is planned for Q3/2021.

The new website (www.mllseq.com) presents MLLSEQ's entire sequencing offering. In addition, explanations have been compiled in the site's Glossary to make it easier to classify elementary terminology. In addition, links to publications and relevant papers on MLL sequencing projects and topics such as whole genome sequencing and RNASeq can be found under Publications. If you have any questions, please do not hesitate to contact MLL and MLLSEQ via the contact form on the MLLSEQ page or via email to info@mllseq.com.

Press Release

MLL Münchner Leukämielabor GmbH

MLL Münchner Leukämielabor GmbH is a nationally as well as internationally active laboratory working to diagnose cases of leukemia and lymphoma. The expertise embedded within the company along with its excellent quality assurance and turnaround times guarantee optimal test procedures for suspected diagnoses of leukemia or lymphoma. In addition, modern equipment and state-of-the-art analysis methods lead to optimal diagnostics for patients. Münchner Leukämielabor is one of the world's leading companies when it comes to the wide range of its diagnostics portfolio. The combination of interconnected methods of cytomorphology, chromosome analysis, FISH, immunophenotyping, and a large number of molecular genetic test procedures makes it possible to gain a comprehensive picture of the existing illness in order to subsequently ensure optimal, customized medical treatment for patients.

Media contact: Sarah Kurz; presse@mll.com; 0049 (0)89 99017-547